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Quantifying the genetic correlation between cancers can provide important insights into the
mechanisms driving cancer etiology. Using genome-wide association study summary sta-
tistics across six cancer types based on a total of 296,215 cases and 301,319 controls of
European ancestry, here we estimate the pair-wise genetic correlations between breast,
colorectal, head/neck, lung, ovary and prostate cancer, and between cancers and 38 other
diseases. We observed statistically significant genetic correlations between lung and head/
neck cancer (rg= 0.57, p= 4.6 × 10−8), breast and ovarian cancer (rg= 0.24, p= 7 × 10−5),
breast and lung cancer (rg= 0.18, p =1.5 × 10−6) and breast and colorectal cancer (rg= 0.15,
p= 1.1 × 10−4). We also found that multiple cancers are genetically correlated with non-
cancer traits including smoking, psychiatric diseases and metabolic characteristics. Functional
enrichment analysis revealed a significant excess contribution of conserved and regulatory
regions to cancer heritability. Our comprehensive analysis of cross-cancer heritability sug-
gests that solid tumors arising across tissues share in part a common germline genetic basis.
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Inherited genetic variation plays an important role in canceretiology. Large twin studies have demonstrated an excessfamilial risk for cancer sites including, but not limited to,
breast, colorectal, head/neck, lung, ovary, and prostate with
heritability estimates ranging between 9% (head/neck) to 57%
(prostate)1–3. Data from nation-wide and multi-generation
registries further show that elevated cancer risks go beyond
nuclear families and isolated types, as family history of a specific
cancer can increase risk for other cancers4–6. Additional evidence
for a shared genetic component have been demonstrated by
cross-cancer genome-wide association study (GWAS) meta-ana-
lyses, which set out to identify genetic variants associated with
more than one cancer type. Fehringer et al. studied breast, col-
orectal, lung, ovarian, and prostate cancer, and identified a novel
locus at 1q22 associated with both breast and lung cancer7. Kar
et al. focused on three hormone-related cancers (breast, ovarian,
and prostate), and identified seven novel susceptibility loci shared
by at least two cancers8.
Previous attempts to estimate the genetic correlation across
cancers using GWAS data9–12 have mostly relied on restricted
maximum likelihood (REML) implemented in GCTA (genome-
wide complex trait analysis)13 and individual-level genotype data.
However, these studies have had limited sample sizes, yielding
inconclusive results. Sampson et al. quantified genetic correlations
across 13 cancers in European ancestry populations and identified
four cancer pairs with nominally significant genetic correlations
(bladder–lung, testis–kidney, lymphoma–osteosarcoma, and
lymphoma–leukemia)9. They did not observe any significant
genetic correlations across common solid tumors including can-
cers of the breast, lung and prostate9. REML becomes computa-
tionally challenging for large sample sizes and is sensitive to
technical artifacts. LD score regression (LDSC)14,15 overcomes
these issues by leveraging the relationship between association
statistics and LD patterns across the genome. We recently used
cross-trait LDSC to quantify genetic correlations across six cancers
based on a subset of the data included here and found moderate
correlations between colorectal and pancreatic cancer, as well as
between lung and colorectal cancer16. However, the average
sample size was only 11,210 cases and 13,961 controls per cancer,
resulting in imprecise estimates with wide confidence intervals.
In addition to the development of novel analytical methods
tailored to genomic data, several high-quality functional anno-
tations have recently been released into the public domain
through large-scale efforts. For example, the ENCODE con-
sortium has built a comprehensive and informative parts list of
functional elements in the human genome (http://www.nature.
com/encode/#/threads), which allows for the analysis of compo-
nents of SNP-heritability to unravel the functional architecture of
complex traits.
Here, we use summary statistics from the largest-to-date Eur-
opean ancestry GWAS of breast, colorectal, head/neck, lung,
ovary, and prostate cancer with an average sample size of 49,369
cases and 50,219 controls per cancer, to quantify genetic corre-
lations between cancers and their subtypes. We also use GWAS
summary statistics for 38 non-cancer traits (average N= 113,808
per trait), to quantify the genetic correlations between the six
cancers and other diseases. Furthermore, we assessed the pro-
portion of cancer heritability attributable to specific functional
categories, with the goal of identifying functional elements that
are enriched for SNP-heritability.
Our comprehensive analysis identifies statistically significant
genetic correlations between lung and head/neck cancer, breast
and ovarian cancer, breast and lung cancer, and breast and col-
orectal cancer. We also find multiple cancers to be genetically
correlated with non-cancer traits including smoking, psychiatric
diseases, and metabolic traits. Functional enrichment analysis
reveals a significant contribution of conserved and regulatory
regions to cancer heritability. Our results suggest that solid
tumors arising across tissues share in part a common germline
genetic basis.
Results
Heritability estimates across cancers. We first estimated cancer-
specific heritability causally explained by common SNPs (h2g)
using LDSC (note that this quantity is slightly different from the
h2g as defined in Yang et al.
17 which estimates the heritability due
to genotyped and imputed SNPs) (see Methods). Estimates of h2g
on the liability scale ranged from 0.03 (ovarian) to 0.25 (prostate)
(Supplementary Table 1). After removing genome-wide sig-
nificant (p < 5 × 10−8) loci, defined as all SNPs within 500 kb of
the most significant SNP in a given region (Supplementary
Data 1), we observed an ~50% decrease in SNP-heritability for
prostate and breast cancer, and ~20% decrease for lung, ovarian,
and colorectal cancer, despite the fact that we were only excluding
1% (colorectal cancer) to 5% (breast cancer) of the genome. In
contrast, the SNP-heritability for head/neck cancer was not
affected by removing genome-wide significant loci (Fig. 1a). For
most of the cancers, the GWAS significant loci for that particular
cancer explained most of the heritability. For some cancers,
however, significant GWAS loci of other cancers also explained a
non-trivial part of its heritability. For example, the significant
breast cancer GWAS loci explained 10%, 15%, and 22% herit-
ability of colorectal, ovarian and prostate cancer, respectively; the
significant colorectal cancer GWAS loci explained 11% herit-
ability of prostate cancer; the significant lung cancer GWAS loci
explained 10% heritability of head/neck cancer; and the sig-
nificant prostate cancer GWAS loci explained 11 and 15% her-
itability of breast and ovarian cancer, respectively (Supplementary
Table 2). Comparing the liability-scale SNP-heritability to cor-
responding estimates from twin studies suggests that common
SNPs can almost entirely explain the classical heritability of head/
neck cancer, whereas for other cancers, only 30–40% of herit-
ability can be explained (Fig. 1b).
Genetic correlations between cancers. We then estimated the
genetic correlation between cancers using cross-trait LDSC (see
Methods). After adjusting for the number of tests (p < 0.05/15=
0.003), we found multiple significant genetic correlations Fig. 1c
and Supplementary Table 1), with the strongest result observed
for lung and head/neck cancer (rg= 0.57, se= 0.10). In addition,
colorectal and lung cancer (rg= 0.28, se= 0.06), breast and
ovarian cancer (rg= 0.24, se=0.06), breast and lung cancer (rg=
0.18, se= 0.04), and breast and colorectal cancer (rg= 0.15, se=
0.04) showed statistically significant genetic correlations. We also
observed nominally significant genetic correlations (p < 0.05)
between lung and ovarian cancer (rg= 0.16, se= 0.08), prostate
cancer and head/neck (rg= 0.15, se= 0.08), colorectal (rg= 0.11,
se= 0.05), and breast cancer (rg= 0.07, se= 0.03) (Fig. 1c). Some
cancer pairs showed minimal correlations with estimates close to
0 (ovarian and prostate: rg= 0.02, se= 0.07; lung and prostate:
rg=−0.03, se= 0.04; breast and head/neck: rg= 0.03, se= 0.06).
We further calculated the cross-cancer genetic correlation based
on data after excluding the GWAS significant regions of each
cancer. The estimates were mostly consistent with the results
calculated based on all SNPs.
We conducted subtype-specific analysis for breast, lung,
ovarian, and prostate cancer (Supplementary Table 1). Estrogen
receptor positive (ER+) and negative (ER−) breast cancer
showed a genetic correlation of 0.60 (se= 0.03), indicating that
the genetic contributions to these two subtypes are in part
distinct. The genetic correlation between the two common lung
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cancer subtypes adenocarcinoma and squamous cell carcinoma
was similarly 0.58 (se= 0.10). Further, we observed a significantly
larger genetic correlation of lung cancer with ER− (rg= 0.29,
se= 0.06) than with ER+ breast cancer (rg= 0.13, se= 0.04)
(pdifference= 0.002). This also held true for lung squamous cell
carcinoma, which showed statistically stronger genetic correlation
with ER− (rg= 0.33, se= 0.08) than with ER+ breast cancer
(rg= 0.11, se= 0.05) (pdifference= 0.0019). We observed no other
statistically significant differential genetic correlations across
subtypes (all pdifference > 0.1).
We then estimated local genetic correlations between cancers
using ρ-HESS, dividing the genome into 1703 regions (see
Methods) (Fig. 2 and Supplementary Fig. 1). We found that
although the genome-wide genetic correlation between breast
and prostate cancer was modest (rg= 0.07), chr10:123M
(10q26.13, p= 1.0 × 10−7) and chr9:20–22 M (9p21, p= 1.0 ×
10−6), two previously known pleiotropic regions18, showed
significant genetic correlations (rg=−0.00098 and rg=
0.00046). Similarly, although the genome-wide genetic correla-
tion between lung and prostate cancer was negligible (rg=
−0.03), two previously identified pleiotropic regions
(chr6:30–31 M or 6p21.33, p= 5.7 × 10−7 and chr20:62M or
20q13.33, p= 2.8 × 10−6) exhibited significant local genetic
correlations (rg=−0.00060 and rg= 0.00067). Overall, local
genetic correlation analysis reinforced shared effects for 44%
(31/71) of previously reported pleiotropic cancer regions
(Supplementary Data 2). It also identified novel pleiotropic
signals. For example, the breast and prostate cancer pleiotropic
region at 2q33.1 showed significant local genetic correlation
between breast and ovarian cancer (p= 2.3 × 10−6). Addition-
ally, 6p21.32, a region indicated for head/neck and prostate
cancer, showed highly significant local genetic correlation for
head/neck and lung cancer (p= 8.6 × 10−8).
Genetic correlations between cancer and other traits. Sig-
nificant genetic correlations (p < 0.05/228= 0.0002) between the
six cancers and 38 non-cancer traits reflected several known
associations (Fig. 3 and Supplementary Data 3). We observed a
strong genetic correlation between smoking and lung cancer
(rg= 0.56, se= 0.06), and similarly for head/neck cancer (rg=
0.47, se= 0.08), both cancers having smoking as its primary risk
factor19,20. Educational attainment was negatively genetically
correlated with colorectal (rg=−0.17, se= 0.04), head/neck
(rg=−0.42, se= 0.07), and lung cancer (rg=−0.39, se=0.04) (all
p < 5 × 10−6). Body mass index (BMI) showed a positive genetic
correlation with colorectal cancer (rg= 0.15, se= 0.03) and also
suggestive but weak negative correlations with prostate (rg=
−0.07, se= 0.03) and breast cancer (rg=−0.06, se= 0.03). Lung
cancer showed a negative genetic correlation with lung function
(rg=−0.15, se= 0.04) and age at natural menopause (rg=−0.25,
se= 0.05), and moderate positive genetic correlations with
depressive symptoms (rg= 0.25, se=0.06) and waist-to-hip ratio
(rg= 0.16, se= 0.04). Breast cancer showed a positive genetic
correlation with schizophrenia (rg= 0.14, se= 0.03).
We did not find evidence of genetic correlations between cancer
and several previously suggested risk factors21–23 including
cardiovascular traits (coronary artery disease, hypertension, and
blood pressure) or sleep characteristics (chronotype, duration, and
insomnia). Further, we did not observe genetic correlations
between cancer and circulating lipids (HDL, LDL, and triglycer-
ides) or type 2 diabetes-related traits except a significant
negative correlation between HDL and lung cancer
(rg=−0.14, se= 0.04). We observed no significant genetic
correlation between breast cancer and age at menarche
(rg=−0.03, se= 0.03) or age at natural menopause (rg=−0.01,
se= 0.03). We also did not observe notable genetic correlations
between cancer and autoimmune inflammatory diseases or height.
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Fig. 1 Estimates of SNP-heritability (h2g) and cross-cancer heritability (rg) for the six cancer types. SNP-heritability and cross-cancer heritability are
calculated based on HapMap3 SNPs using LD score regression (LDSC). a The solid bar represents overall SNP h2g on the liability scale, calculated based on
all HapMap3 SNPs. The dark green bar represents h2g calculated based on non-significant SNPs—the remaining SNPs after excluding genome-wide
significant hits (p < 5 × 10−8) ± 500 kb. The black bar with density texture indicates proportion of h2g (as reflected by the percentages displayed on top of
each bar) that could be explained by top hits ±500 kb surrounded areas. The orange error bars represent 95% confidence intervals. b The solid blue bar
represents overall SNP h2g in liability scale (no SNP exclusion), with black error bars indicating 95% confidence intervals. The red short lines correspond to
classical estimates of h2 measured in a twin study of Scandinavian countries (Mucci et al.2). c Genetic correlations between cancers. Estimates withstood
Bonferroni corrections (p < 0.05/15) are marked with double asterisk (**), and nominal significant results (p < 0.05) are marked with single asterisk (*)
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Fig. 2 Local genetic correlation between breast, lung and prostate cancer. The region-specific p-values for the local genetic covariance for breast and
prostate cancer are shown in a, and for lung and prostate cancer in b. Each dot presents a specific genomic region. In the QQ plots, red color indicates
significance after multiple corrections (p < 0.05/1703 regions compared), and blue color indicates nominal significance (p < 0.05/15 pairs of cancers
compared). Manhattan-style plots showing the estimates of local genetic covariance for breast and prostate cancer (c), and for lung and prostate cancer
(d). Although breast and prostate cancer only show modest genome-wide genetic correlation, two loci exhibit significant local genetic covariance. Similarly,
albeit the negligible overall genetic correlation for lung and prostate cancer, three loci present significant local genetic covariance. In the Manhattan plots,
red color indicates even number chromosomes and blue color indicates odd number chromosomes
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Subtype analysis revealed that smoking and educational
attainment showed genetic correlations with all lung cancer
subtypes (Supplementary Data 3). Educational attainment, forced
vital capacity and depressive symptoms showed genetic correla-
tions with ER− but not ER+ breast cancer, whilst the observed
genetic correlation between schizophrenia and breast cancer was
limited to ER+ disease, and the genetic correlation between
depressive symptoms and lung cancer was observed only for lung
squamous cell carcinoma.
We further assessed the support for mediated or pleiotropic
causal models for non-cancer traits and cancer using the
correlation between trait-specific effect sizes of genome-wide
significant SNPs for pairs of phenotypes. We detected four
putative directional genetic correlations (defined as p < 0.05 from
a likelihood ratio (LR) comparing the best non-causal model to
the best causal model) (Fig. 4), where SNPs associated with the
non-cancer trait showed correlated effect estimates with cancer
but the reverse was not true (circulating HDL concentrations and
breast cancer, LRnon-causal vs. causal= 0.04, schizophrenia and
breast cancer, LRnon-causal vs. causal= 0.003, age at natural
menopause and breast cancer, LRnon-causal vs. causal= 0.04, and
lupus and prostate cancer, LRnon-causal vs. causal= 0.0006).
Functional enrichment analysis of cancer heritability. Finally,
we partitioned SNP-heritability of each cancer by using 24
genomic functional annotations (the baseline-LD model descri-
bed in Gazal et al.24) and 220 cell-type-specific histone mark
annotations (the cell-type-specific model described in Finucane
et al.14). Meta-analysis across the six cancers revealed statistically
significant enrichments for multiple functional categories.
We observed the highest enrichment for conserved regions
(Table 1, Supplementary Table 3) which overlapped with
only 2.6% of SNPs but explained 25% of cancer SNP-heritability
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Fig. 3 Cross-trait genetic correlation (rg) analysis between cancers and non-cancer traits. The traits were divided into four categories: a Common
phenotypes, b Metabolic or cardiovascular related traits, c Psychiatric traits, d Autoimmune inflammatory diseases. Pair-wise genetic correlations
withstood Bonferroni corrections (228 tests) are marked with double asterisk (**), with estimates of correlation shown in the cells. Pair-wise genetic
correlations with significance at p < 0.01 are marked with a single asterisk (*). The color of cells represents the magnitude of correlation
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(9.8-fold enrichment, p= 2.3 × 10−5). Transcription factor bind-
ing sites showed the second highest enrichment (4.0-fold, 13% of
SNPs explaining 40% of SNP-heritability, p= 1.4 × 10−7). Fur-
ther, super-enhancers (groups of putative enhancers in close
genomic proximity with unusually high levels of mediator bind-
ing) showed a significant 2.6-fold enrichment (p= 2.0 × 10−20).
Additional enhancers, including regular enhancers (3.2-fold),
weak enhancers (3.1-fold) and FANTOM5 enhancers (3.1-fold),
presented similar enrichments but were not statistically sig-
nificant. In addition, multiple histone modifications of epigenetic
markers H3K9ac, H3K4me3, and H3K27ac, were all significantly
enriched for cancer heritability. Repressed regions exhibited
depletion (0.34-fold, p= 1.2 × 10−6). Enrichment analysis of
functional categories for each cancer and cancer subtype are
shown in Fig. 5 and Supplementary Table 4.
Overall, cell-type-specific analysis of histone marks identified
significant enrichments specific to individual cancers (Supple-
mentary Fig. 2). For breast cancer, 3 out of 8 statistically
significant tissues were adipose nuclei (H3K4me1, H3K9ac) and
breast myoepithelial (H3K4me1) cells. For colorectal cancer, 15
out of the 18 statistically significant enrichments were observed in
either colon or rectal tissues (colon/rectal mucosa, duodenum
mucosa, small/large intestine, and colon smooth muscle). We
observed no significant enrichments for head/neck, lung, and
ovarian cancer, but we noted that for both lung (9 out of 10) and
ovarian cancer (6 out of 10), the most enriched cell types were
immune cells; while in head/neck cancer, 6 out of 10 most highly
enriched cell types belonged to CNS (Supplementary Fig. 3,
Supplementary Data 4). Cell-type-specific analysis for cancer
subtypes are shown in Supplementary Data 5. Comparing
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Fig. 4 Putative directional relationships between cancers and traits. For each cancer–trait pair identified as candidates to be related in a causal manner, the
plots show trait-specific effect sizes (beta coefficients) of the included genetic variants. Gray lines represent the relevant standard errors. a HDL and breast
cancer. Trait-specific effect sizes for HDL and breast cancer are shown for SNPs associated with HDL levels (left) and breast cancer (right).
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shown for SNPs associated with age at natural menopause (left) and breast cancer (right). d Lupus and prostate cancer. Trait-specific effect sizes for lupus
and prostate cancer are shown for SNPs associated with lupus (left) and prostate cancer (right)
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cell-type-specific enrichment for cancers to the additional 38
non-cancer traits revealed notably differential clustering patterns
(Supplementary Fig. 4). Breast, colorectal, and prostate cancer
showed enrichment mostly for adipose and epithelial tissues, in
contrast to autoimmune diseases (enriched for immune/hemato-
poietic cells) or psychiatric disorders (enriched for brain tissues).
Discussion
We performed a comprehensive analysis quantifying the herit-
ability and genetic correlation of six cancers, leveraging summary
statistics from the largest cancer GWAS conducted to date. Our
study demonstrates shared genetic components across multiple
cancer types. These results contrast with a prior study conducted
by Sampson et al. which reported an overall negligible genetic
correlation among common solid tumors9. Our results are,
however, in line with a recent study,16 which analyzed a subset of
the data included here, and identified a significant genetic cor-
relation between lung and colorectal cancer.
Our data support, and for the first time quantify, the strong
genetic correlation (rg= 0.57) between lung and head/neck can-
cer, two cancers linked to tobacco use20,25. We also for the first
time observed a significant genetic correlation between breast and
ovarian cancer (rg= 0.24), two cancers that are known to share
rare genetic factors including BRCA1/2 mutations, and environ-
mental exposures associated with endogenous and exogenous
hormone exposures26. Prostate cancer is also considered as
hormone-dependent and associated with BRCA1/2mutations, but
interestingly, we only observed a nominally significant and
modest (rg= 0.07) genetic correlation between breast and pros-
tate cancer, while ovarian and prostate cancer showed no genetic
correlation (rg= 0.02, se= 0.07).
Our large sample sizes allowed us to conduct well-powered
analyses for cancer subtypes. While head/neck cancer showed
negligible genetic correlation with overall (rg= 0.03, se= 0.06)
and ER+ breast cancer (rg=−0.02, se= 0.07), it showed a
stronger genetic correlation with ER− breast cancer (rg= 0.21,
se= 0.09). Similarly, lung cancer showed a statistically more
pronounced genetic correlation with ER− (rg= 0.29, se= 0.06)
than ER+ breast cancer (rg= 0.13, se= 0.04). A recent pooled
analysis of smoking and breast cancer risk demonstrated a
smoking-related increased risk for ER+ but not for ER− breast
cancer27, and thus it is unlikely that the stronger genetic corre-
lation between ER− subtype and lung and head/neck cancer is
due to smoking behavior. Perhaps surprisingly, despite literature
suggesting substantial similarities between ER− breast cancer and
serous ovarian cancer in particular28, we did not observe statis-
tically significant different genetic correlations between ER− or
ER+ breast cancer and serous ovarian cancer (rg= 0.17, se=
0.08 vs. rg= 0.11, se= 0.06). This suggests that rare high pene-
trance variants may play a more important role in driving the
similarities behind ER− breast cancer and serous ovarian cancer
than common genetic variation.
Heritability analysis confirms that common cancers have a
polygenic component that involves a large number of variants.
Although susceptibility variants identified at genome-wide sig-
nificance explain an appreciable fraction of the heritability for
some cancers, we estimate that the majority of the polygenic effect
is attributable to other, yet undiscovered variants, presumably
with effects that are too weak to have been identified with current
sample sizes. We found the genetic component that could be
attributed to genome-wide significant loci varied greatly from
~0% for head/neck cancer to ~50% for breast and prostate cancer.
These results reflect in part the strong correlation between
number of GWAS-identified loci and sample size, as we had more
than twice as many breast and prostate cancer samples compared
to the other cancers. One corollary is that larger GWAS are likely
to identify new susceptibility loci that could help our under-
standing of disease development, improve prediction power of
genetic risk scores and hence contribute to screening and per-
sonalized risk prediction29.
Among the genetic correlations between cancer and non-
cancer traits, we observed positive correlations for psychiatric
disorders (depressive symptoms, schizophrenia) with lung and
breast cancer, where findings from epidemiological studies have
been suggestive but inconclusive. It has been proposed that the
linkage between psychiatric traits and cancers are more likely to
be mediated through cancer-associated risk phenotypes such as
smoking, excessive alcohol consumption in depressed popula-
tions30, and reduced fertility patterns (e.g., nulliparous) in psy-
chiatric populations31. Detailed analyses considering confounding
traits like reproductive history and smoking are needed to make
inference about the mechanisms involved. GWAS have identified
pleiotropic regions influencing both lung cancer and nicotine
dependence, such as 15q25.132,33. In line with those results, we
identified a strong genetic correlation between smoking and both
lung (rg= 0.56) and head/neck cancer (rg= 0.47). It remains
unclear whether this genetic correlation is completely explained
by the direct influence of smoking or if the shared genetic com-
ponent affects the traits through separate pathways. Interestingly,
a genetic correlation (rg= 0.35, se= 0.14) between lung and
bladder cancer, another smoking-associated cancer, has been
identified previously9. Due to the small numbers of GWAS-
identified smoking-associated SNPs, we were unable to assess a
directional correlation between smoking and cancer, but we
expect such analyses to become feasible as additional smoking-
related SNPs are identified. We found modest positive, yet sig-
nificant genetic correlations between adiposity-related measures
(as reflected by waist-to-hip ratio, circulating HDL levels and
BMI) and both colorectal and lung cancer, but negative genetic
correlations between BMI and prostate and breast cancer, con-
sistent with previous reported findings34 and reinforce the com-
plex dynamics between obesity and cancer where multiple factors
including age, smoking, endogenous hormones and reproductive
status play a role.
We did not observe genetic correlations between breast cancer
and age at menarche or age at natural menopause. These null
observations were largely driven by ER+ breast cancer (ER+ :
rg= 0.006, se= 0.03 vs. ER−: rg=−0.09, se= 0.04 for age
at menarche. ER+ : rg= 0.0005, se= 0.04 vs. ER−: rg=−0.10,
se= 0.05 for age at natural menopause), and were unexpected
given that both factors play pivotal roles in breast cancer etiol-
ogy35 and previous Mendelian randomization (MR) analyses have
identified a link36,37. An important difference between genetic
Table 1 Significant enrichment estimates of genomic
functional categories, meta-analyzed across six cancer sites
Category Enrichment (95% CI) P-value
Conserved region 9.78 (5.72–13.84) 2.28 × 10−5
TFBS 4.04 (2.91–5.17) 1.43 × 10−7
H3K9ac 3.41 (2.14–4.69) 2.04 × 10−4
H3K4me3 3.23 (2.47–4.00) 8.91 × 10−9
Super Enhancer 2.56 (2.23–2.89) 1.99 × 10−20
H3K27ac (PGC) 2.36 (1.91–2.80) 2.12 × 10−9
H3K27ac (Hnisz) 1.90 (1.65–2.15) 1.86 × 10−12
H3K4me1 1.84 (1.56–2.12) 2.57 × 10−9
Repressed region 0.34 (0.07–0.61) 1.15 × 10−6
The meta-analysis was performed based on the enrichment estimates and standard errors
calculated using LD score regression in each individual cancer type. P-values were significant
after Bonferroni correction (P < 0.05/24)
TFBS transcription factor binding sites
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Fig. 5 Enrichment p-values of 24 non-cell-type-specific functional categories over six cancer types. The x-axis represents each of the 24 functional
categories, y-axis represents log-transformed p-values of enrichment. Annotations with statistical significance after Bonferroni corrections (p < 0.05/24)
were plotted in orange, otherwise blue. The horizontal gray dash line indicates p-threshold of 0.05; horizontal red dash line indicates p-threshold of 0.05/
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correlation and MR analyses is that the latter only considers
genome-wide significant SNPs while the former incorporates the
entire genome. It is possible that a relatively small overlap in
strongly associated SNPs can result in significant MR results
despite low evidence of an overall genetic correlation. Indeed, the
directional genetic correlations we observed for age at natural
menopause, schizophrenia, and HDL with breast cancer, and for
lupus with prostate cancer, highlight again that although an
overall genetic correlation may be negligible, there can still be
genetic links between traits. It is important to note that we cannot
rule out unmeasured confounding, including the possibility that
these genetic variants affect an intermediate phenotype that is
pleiotropic for both target traits. Given the observational nature
of our data, these putative causal directions should be interpreted
with caution.
Pan-cancer tumor-based studies have demonstrated that dif-
ferent cancers are sometimes driven by similar somatic functional
events such as specific copy number abnormalities and
mutations38,39. Our enrichment results of germline genetic across
functional annotation data shed new light on the biological
mechanisms leading to cancer development. The more pro-
nounced enrichment identified for conserved regions compared
with coding regions provides evidence for the biological impor-
tance of the former, which has been shown to be true for multiple
traits14,40. Even though the biochemical function of many con-
served regions remains uncharacterized, transcribed ultra-
conserved regions have been found to be frequently located at
fragile sites. Compared to normal cells, cancer cells have a unique
spectrum of transcribed ultra-conservative regions, suggesting
that variation in expression of these regions are involved in the
malignant process41,42. These results bridge the link between
germline and somatic genetics in cancer development, which was
also observed in a recent breast cancer GWAS that has demon-
strated a strong overlap between target genes for GWAS hits and
somatic driver genes in breast tumors43. We also found a four-
fold enrichment for transcription factor binding sites and a three-
fold enrichment for super-enhancers, consistent with prior
observations that breast cancer GWAS loci fall in enhancer
regions involved in distal regulation of target genes43. Cell-type-
specific analysis of histone marks demonstrated the importance of
tissue specificity, primarily for colorectal and breast cancer.
Further, our results suggest that immune cells are important for
ovarian and lung cancer whilst CNS is important to head/neck
cancer. Unfortunately, we did not have data on prostate-specific
tissues, but we note that tissue-specific enrichment of prostate
cancer heritability for epigenetic markers has been observed
previously10. We note that generation of rich functional anno-
tation is ongoing and we expect to include additional tissue-
specific functional elements in our future work.
Our study has several strengths. We were able to robustly
quantify pair-wise genetic correlations between multiple cancers
using the largest available cancer GWAS, comprising almost
600,000 samples across six major cancers and subtypes. We were
also able to systematically assess the genetic correlations between
cancer and 38 non-cancer traits. Notwithstanding the large
sample sizes, several limitations need to be acknowledged. We did
not have the sample sizes required to assess relevant cancer
subgroups including oropharyngeal cancer, clear cell, mucinous
and endometrioid ovarian cancer, or lung cancer among never
smokers (each with ~2000 cases). In addition, we did not have
access to GWAS summary statistics for pre- vs. post-menopausal
breast cancer. We were not able to consider all cancer risk factors
when selecting non-cancer traits, since some of the well-
established risk factors such as infection were either not avail-
able, showed no evidence of heritability or were not based on
adequate sample sizes for robust analyses. SNP-heritability varies
with minor allele frequency, linkage disequilibrium, and genotype
certainty; we note that approaches to estimate heritability lever-
aging GWAS data are constantly evolving. We also note that
estimate variability needs to be taken into account when com-
paring the SNP-heritability with the classical twin-heritability, in
particular for cancers with small sample sizes such as head/neck
cancer (SNP-heritability varied between 5–14% and twin-
heritability varied between 0–60%, although both point esti-
mates were 9%). Further, our data were based on GWAS meta-
analysis from multiple individual GWAS across European
ancestry populations from Europe, Australia and the US. Intra-
European ancestry differences are likely to be a source of bias.
However, since we limited our analysis to SNPs with MAF > 1%
and HapMap3 SNPs (which have proven to be well imputed
across European ancestry populations), we believe that any
population structure across cancers will have minimal effect on
our results. Finally, as more non-European and multi-ethnic
GWAS data become available, it is important to examine trans-
ethnic genetic correlation in cancer.
In conclusion, results from our comprehensive analysis of
heritability and genetic correlations across six cancer types indi-
cate that solid tumors arising from different tissues share com-
mon germline genetic influences. Our results also demonstrate
evidence for common genetic risk sharing between cancers and
smoking, psychiatric, and metabolic traits. In addition, functional
components of the genome, particularly conserved and regulatory
regions, are significant contributors to cancer heritability across
multiple cancer types. Our results provide a basis and direction
for future cross-cancer studies aiming to further explore the
biological mechanisms underlying cancer development.
Methods
Studies and quality control. We used summary statistics from six cancer GWASs
based on a total of 597,534 participants of European ancestry. Cancer-specific
sample sizes were: breast cancer: 122,977 cases/105,974 controls; colorectal cancer:
36,948/30,864; head/neck cancer (oral and oropharyngeal cancers): 5452/5984; lung
cancer: 29,266/56,450; ovarian cancer: 22,406/40,941; prostate cancer: 79,166/
61,106. These data were generated through the joint efforts of multiple consortia.
Details on study characteristics and subjects contributed to each cancer-specific
GWAS summary dataset have been described elsewhere43–49. SNPs were imputed
to the 1000 Genomes Project reference panel (1KGP) using a standardized protocol
for all cancer types18. We included autosomal SNPs with a minor allele frequency
(MAF) larger than 1% and present in HapMap3 (NSNPs= ~1 million) because
those SNPs are usually well imputed in most studies (note that excluding sex
chromosomes could reduce the overall heritability estimates). A brief overview of
the quality control in each cancer dataset are presented in Supplementary Table 5.
For some of the cancers, we further obtained summary statistics data on subtypes
(ER+ and ER− breast cancer; lung adenocarcinoma, and squamous cell carci-
noma; serous invasive ovarian cancer and advanced stage prostate cancer, defined
as metastatic disease or Gleason score ≥ 8 or PSA > 100 or prostate cancer death).
Sample sizes and more details shown in Supplementary Table 1.
We additionally assembled European ancestry GWAS summary statistics from
38 traits, which spanned a wide range of phenotypes including anthropometric
(e.g., height and body mass index (BMI)), psychiatric disorder (e.g., depressive
symptoms and schizophrenia), and autoimmune disease (e.g., rheumatoid arthritis
and celiac disease) (Supplementary Table 6). We calculated trait-specific SNP-
heritability and restricted our analysis to traits with a heritable component
(Supplementary Table 7)14. We removed the major histocompatibility complex
(MHC) region from all analysis because of its unusual LD and genetic architecture.
Estimation of SNP-heritability and genetic correlation. We estimated the SNP-
heritability due to genotyped and imputed SNPs (h2g , the proportion of phenotypic
variance causally explained by common SNPs) of each cancer using LDSC15.
Briefly, this method is based on the relationship between LD score and χ2-statistics:
E χ2j
h i
 Njh
2
g
M
lj þ 1 ð1Þ
where E χ2j
h i
denotes the expected χ2-statistics for the association between the
outcome and SNP j, Nj is the study sample size available for SNP j, M is the total
numbers of variants and lj denotes the LD score of SNP j defined as lj ¼
P
k
r2 j; kð Þ
(k denotes other variants within the LD region). Note that the quantity estimated
by LDSC is the causal heritability of common SNPs, which is different from the
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SNP-heritability as defined in Yang et al.17. To estimate h2g attributable to undis-
covered loci, we identified SNPs that were associated with a given cancer at
genome-wide significance (p < 5 × 10−8) and removed all SNPs within (+/−)
500,000 base-pairs of those loci prior to calculation (number of regions (+/−
500 kb) for each cancer that reach the 5 × 10−8 threshold and measures of effect
size are shown in Supplementary Data 1). We also converted the SNP-heritability
from observed scale to liability scale by incorporating sample prevalence (P) and
population prevalence (F) of each cancer:
h2liability ¼ h2observed
F 1 Fð Þ
ϕ Φ1 Fð Þð Þ2
F 1 Fð Þ
P 1 Pð Þ ð2Þ
We subsequently calculated the genome-wide genetic correlations (rg) between
different cancers, and between cancers and non-cancer traits, using an algorithm14:
E βjγj
h i
¼
ffiffiffiffiffiffiffiffiffiffiffi
N1N2
p
rg
M
lj þ
Nsrffiffiffiffiffiffiffiffiffiffiffi
N1N2
p ð3Þ
where βj and γj are the effect sizes of SNP j on traits 1 and 2, rg is the genetic
covariance, M is number of SNPs, N1 and N2 are the sample sizes for trait 1 and 2,
Ns is the number of overlapping samples, r is the phenotypic correlation in
overlapping samples and lj is the LD score defined as above. For genetic correlation
between 6 cancers, the significance level is 0.05/15= 0.003; for genetic correlation
between 6 cancers and 38 traits, the significance level is 0.05/(6 × 38)= 0.0002.
Overall genetic correlations as estimated by LDSC are based on aggregated
information across all variants in the genome. It is possible that even though two
traits show negligible overall genetic correlation, there are specific regions in the
genome that contribute to both traits. We therefore examined local genetic
correlations between cancer pairs using ρ-HESS50, an algorithm which partitions
the whole genome into 1703 regions based on LD-pattern of European populations
and quantifies correlation between pairs of traits due to genetic variation restricted
to these genomic regions. Local genetic correlation was considered statistically
significant if p < 0.05/1,703= 2.9 × 10−5. In particular, we assessed the local genetic
correlations for previously reported pleiotropic regions18,51 known to harbor SNPs
affecting multiple cancers.
Directional genetic correlation analysis. In addition to the genetic correlation
analysis, which reflects overall genetic overlaps, we also attempted to identify
directions of potential genetic correlations using a subset of SNPs as proposed by
Pickrell et al.52. The method adopts the following assumption: if a trait X influences
trait Y, then SNPs influencing X should also influence Y, and the SNP-specific
effect sizes for the two traits should be correlated. Further, since Y does not
influence X, but could be influenced by mechanisms independent of X, genetic
variants that influence Y do not necessarily influence X. Based on this assumption,
the method proposes two causal models and two non-causal models; and calculates
the relative likelihood ratio (LR) of the best non-causal model compared to the best
causal model. We determined significant SNPs for each given cancer or trait in two
independent ways, (1) LD pruned SNPs: we selected genome-wide significant (p <
5 × 10−8) SNPs and pruned on LD-pattern in the European populations in Phase1
of 1KGP; (2) posterior probability of association (PPA) SNPs: we used a method
implemented in fgwas53, which splits the genome into independent blocks based on
LD patterns in 1KGP and estimates the prior probability that any block contains an
association. The model outputs posterior probability that the region contains a
variant that influences the trait. We selected the lead SNP from each of the
regions with a PPA of at least 0.9. We scanned through all pairs of cancers
and traits to identify directional correlations. Only pairs of traits with evidence
of directional correlations (LR comparing the best non-causal model over
the best causal model < 0.05) and without evidence of heteroscedasticity
(pleiotropic effects)54 were reported as relatively more likely to exhibit mediated
causation.
Functional partitioning of SNP-heritability. To assess the importance of specific
functional annotations in SNP-heritability across cancers, we partitioned the
cancer-specific heritability using stratified-LDSC14. This method partitions SNPs
into functional categories and calculates category-specific enrichments based on the
assumption that a category of SNPs is enriched for heritability if SNPs with high
LD to that category have higher χ2 statistics than SNPs with low LD to that
category. The analysis was performed using two models14,24.
1. A full baseline-LD model including 24 publicly available annotations that are
not specific to any cell type. When performing this model, we adjusted for
MAF via MAF-stratified quantile-normalized LD score, and other LD-related
annotations such as predicted allele age and recombination rate, as
implemented by Gazal et al.24. Briefly, the 24 annotations included coding,
3′UTR and 5′UTR, promoter and intronic regions, obtained from UCSC
Genome Browser and post-processed by Gusev et al.55; the histone marks
mono-methylation (H3K4me1) and tri-methylation of histone H3 at lysine 4
(H3K4me3), acetylation of histone H3 at lysine 9 (H3K9ac) processed by
Trynka et al.56–58 and two versions of acetylation of histone H3 at lysine 27
(H3K27ac, one version processed by Hnisz et al.59, another used by the
Psychiatric Genomics Consortium (PGC)60); open chromatin, as reflected by
DNase I hypersensitivity sites (DHSs and fetal DHSs)55, obtained as a
combination of ENCODE and Roadmap Epigenomics data, processed by
Trynka et al.58; combined chromHMM and Segway predictions obtained from
Hoffman et al.61, which make use of many annotations to produce a single
partition of the genome into seven underlying chromatin states (The CCCTC-
binding factor (CTCF), promoter-flanking, transcribed, transcription start site
(TSS), strong enhancer, weak enhancer categories, and the repressed
category); regions that are conserved in mammals, obtained from Lindblad-
Toh et al.40 and post-processed by Ward and Kellis62; super-enhancers, which
are large clusters of highly active enhancers, obtained from Hnisz et al.59;
FANTOM5 enhancers with balanced bi-directional capped transcripts
identified using cap analysis of gene expression in the FANTOM5 panel of
samples, obtained from Andersson et al.63; digital genomic footprint (DGF)
and transcription factor binding site (TFBS) annotations obtained from
ENCODE and post-processed by Gusev et al.55
2. In addition to the baseline-LD model, we also performed analyses using 220 cell-
type-specific annotations for the four histone marks H3K4me1, H3K4me3,
H3K9ac, and H3K27ac. Each cell-type-specific annotation corresponds to a
histone mark in a single cell type (for example, H3K27ac in CD19 immune
cells), and there were 220 such annotations in total. We further divided these 220
cell-type-specific annotations into 10 groups (adrenal and pancreas, central
nervous system (CNS), cardiovascular, connective and bone, gastrointestinal,
immune and hematopoietic, kidney, liver, skeletal muscle, and other) by taking a
union of the cell-type-specific annotations within each group (for example, SNPs
with any of the four histone modifications in any hematopoietic and immune
cells were considered as one big category). When generating the cell-type-
specific models, we added annotations individually to the baseline model,
creating 220 separate models.
We performed a random-effects meta-analysis of the proportion of heritability
over six cancers for each functional category. We set significance thresholds for
individual annotations at p < 0.05/24 for baseline model and at p < 0.05/220 for
cell-type-specific annotation.
Data availability
The datasets generated during and/or analyzed during the current study are
available from the authors on request. Breast cancer: summary results for all
variants are available at http://bcac.ccge.medschl.cam.ac.uk/. Requests for further
data should be made through the Data Access Coordination Committee (http://
bcac.ccge.medschl.cam.ac.uk/). Ovarian cancer: summary results are available from
the Ovarian Cancer Association Consortium (OCAC) (http://ocac.ccge.medschl.
cam.ac.uk/). Requests for further data can be made to the Data Access Coordi-
nation Committee (http://cimba.ccge.medschl.cam.ac.uk/). Prostate cancer: sum-
mary results are publicly available at the PRACTICAL website (http://practical.icr.
ac.uk/blog/). Lung cancer: genotype data for lung cancer are available at the
database of Genotypes and Phenotypes (dbGaP) under accession phs001273.v1.p1.
Readers interested in obtaining a copy of the original data can do so by completing
the proposal request form at http://oncoarray.dartmouth.edu/. Head/neck cancer:
genotype data for the oral and pharyngeal OncoArray study have been deposited at
the database of Genotypes and Phenotypes (dbGaP) under accession phs001202.v1.
p1. Colorectal cancer: genotype data have been deposited at the database of
Genotypes and Phenotypes (dbGaP) under accession number phs001415.v1.p1 and
phs001078.v1.p1.
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National Institute of Dental and Craniofacial Research (NIDCR) grant 1 × 01HG007780-
0. The University of Pittsburgh head and neck cancer case-control study is supported by
National Institutes of Health grants P50 CA097190 and P30 CA047904. The Carolina
Head and Neck Cancer Study (CHANCE) was supported by the National Cancer Institute
(R01-CA90731). The Head and Neck Genome Project (GENCAPO) was supported by the
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (Grant numbers 04/
12054-9 and 10/51168-0). The authors thank all the members of the GENCAPO team.
The HN5000 study was funded by the National Institute for Health Research (NIHR)
under its Programme Grants for Applied Research scheme (RP-PG-0707-10034), the
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07-BI060604, FICYT/Asturias grant numbers FICYT PB02-67 and FICYT IB09-133, and
the University Institute of Oncology (IUOPA), of the University of Oviedo and the Ciber
de Epidemiologia y Salud Pública. CIBERESP, SPAIN. The work performed in the
CARET study was supported by the National Institute of Health/National Cancer Insti-
tute: UM1 CA167462 (PI: Goodman), National Institute of Health UO1-CA6367307 (PIs
Omen, Goodman); National Institute of Health R01 CA111703 (PI Chen), National
Institute of Health 5R01 CA151989-01A1(PI Doherty). The Liverpool Lung project is
supported by the Roy Castle Lung Cancer Foundation. The Harvard Lung Cancer Study
was supported by the NIH (National Cancer Institute) grants CA092824, CA090578,
CA074386. The Multi-ethnic Cohort Study was partially supported by NIH Grants
CA164973, CA033619, CA63464, and CA148127. The work performed in MSH-PMH
study was supported by The Canadian Cancer Society Research Institute (020214),
Ontario Institute of Cancer and Cancer Care Ontario Chair Award to R.J.H. and G.L. and
the Alan Brown Chair and Lusi Wong Programs at the Princess Margaret Hospital
Foundation. NJLCS was funded by the State Key Program of National Natural Science of
China (81230067), the National Key Basic Research Program Grant (2011CB503805), the
Major Program of the National Natural Science Foundation of China (81390543). The
Norway study was supported by Norwegian Cancer Society, Norwegian Research Council.
The Shanghai Cohort Study (SCS) was supported by National Institutes of Health R01
CA144034 (PI: Yuan) and UM1 CA182876 (PI: Yuan). The Singapore Chinese Health
Study (SCHS) was supported by National Institutes of Health R01 CA144034 (PI: Yuan)
and UM1 CA182876 (PI: Yuan). The work in TLC study has been supported in part the
James & Esther King Biomedical Research Program (09KN-15), National Institutes of
Health Specialized Programs of Research Excellence (SPORE) Grant (P50 CA119997),
and by a Cancer Center Support Grant (CCSG) at the H. Lee Moffitt Cancer Center and
Research Institute, an NCI designated Comprehensive Cancer Center (grant number P30-
CA76292). The Vanderbilt Lung Cancer Study—BioVU dataset used for the analyses
described was obtained from Vanderbilt University Medical Center’s BioVU, which is
supported by institutional funding, the 1S10RR025141-01 instrumentation award, and by
the Vanderbilt CTSA grant UL1TR000445 from NCATS/NIH. Dr. Aldrich was supported
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